These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34996075)

  • 1. Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders.
    Fiala C; Rotstein D; Pasic MD
    J Appl Lab Med; 2022 Jan; 7(1):305-310. PubMed ID: 34996075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.
    Sharma J; Bhatti MT; Danesh-Meyer HV
    Clin Exp Ophthalmol; 2021 Mar; 49(2):186-202. PubMed ID: 33426799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
    Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica spectrum disorder: pathophysiological approach.
    Mireles-Ramírez MA; Pacheco-Moises FP; González-Usigli HA; Sánchez-Rosales NA; Hernández-Preciado MR; Delgado-Lara DLC; Hernández-Cruz JJ; Ortiz GG
    Int J Neurosci; 2024 Aug; 134(8):826-838. PubMed ID: 36453541
    [No Abstract]   [Full Text] [Related]  

  • 10. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].
    Aktas O; Kümpfel T
    Nervenarzt; 2021 Apr; 92(4):307-316. PubMed ID: 33728474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
    Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Rees JH; Rempe T; Tuna IS; Perero MM; Sabat S; Massini T; Yetto JM
    Magn Reson Imaging Clin N Am; 2024 May; 32(2):233-251. PubMed ID: 38555139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?
    Lee HL; Seok HY; Ryu HW; Cho EB; Kim BC; Kim BJ; Min JH; Seok JM; Shin HY; Kang SY; Kwon OH; Lee SS; Oh J; Sohn EH; Huh SY; Cho JY; Seong JY; Kim BJ
    Mult Scler; 2020 Nov; 26(13):1700-1707. PubMed ID: 31680620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.
    Gospe SM; Chen JJ; Bhatti MT
    Eye (Lond); 2021 Mar; 35(3):753-768. PubMed ID: 33323985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.
    Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K
    Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults.
    Duan Z; Feng J
    J Clin Neurosci; 2022 Jul; 101():89-93. PubMed ID: 35569419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
    J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.